22-Dec-2025
Samsung Biologics acquires Human Genome Sciences from GSK
Seeking Alpha News (Mon, 22-Dec 12:45 AM ET)
PRNewswire (Sun, 21-Dec 5:44 PM ET)
The Week That Was, The Week Ahead: Macro & Markets, Dec. 20
TipRanks (Sun, 21-Dec 4:00 AM ET)
Benzinga (Sat, 20-Dec 1:38 AM ET)
Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out
Benzinga (Fri, 19-Dec 12:43 PM ET)
TD Cowen Remains a Hold on GlaxoSmithKline (GSK)
TipRanks (Thu, 18-Dec 10:45 AM ET)
Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma
Business Wire (Tue, 16-Dec 9:55 PM ET)
Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma
Business Wire (Thu, 23-Oct 8:11 PM ET)
Globe Newswire (Tue, 21-Oct 2:00 AM ET)
GSK Pre-Earnings History Points to a Sharp Rally
Market Chameleon (Mon, 20-Oct 7:01 AM ET)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
GSK PLC American Depositary Shares (Each Representing Two Ordinary Shares) trades on the NYSE stock market under the symbol GSK.
As of December 22, 2025, GSK stock price declined to $48.59 with 2,417,839 million shares trading.
GSK has a beta of 0.33, meaning it tends to be less sensitive to market movements. GSK has a correlation of 0.06 to the broad based SPY ETF.
GSK has a market cap of $98.03 billion. This is considered a Large Cap stock.
Last quarter GSK PLC American Depositary Shares (Each Representing Two Ordinary Shares) reported $12 billion in Revenue and $1.48 earnings per share. This beat revenue expectation by $367 million and exceeded earnings estimates by $.22.
In the last 3 years, GSK traded as high as $49.44 and as low as $31.72.
The top ETF exchange traded funds that GSK belongs to (by Net Assets): PPH, AVDE, FVD, FENI, RODM.
GSK has outperformed the market in the last year with a return of +49.6%, while the SPY ETF gained +17.1%. In the last 3 month period, GSK beat the market returning +19.8%, while SPY returned +3.0%. However, in the most recent 2 weeks GSK has underperformed the stock market by returning +0.2%, while SPY returned +0.5%.
GSK support price is $48.04 and resistance is $49.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GSK shares will trade within this expected range on the day.